Skip to main
CELC

Celcuity (CELC) Stock Forecast & Price Target

Celcuity (CELC) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Celcuity is expected to launch their new drug Revtorpyk in late 2026, with a management team that is fully prepared and has potential for a healthy launch with their strong network and already secured coverage for over 90% of US medical-benefit lives. With current market-competitive pricing for similar oral agents being around $25,000 per month, Celcuity's IV drug could have a higher net price with only a projected 20% gross-to-net discount, making it more profitable. With a strong launch execution expected and the MT population also expected to be approved in late 2026, Celcuity has a strong opportunity in the fragmented 2L PIK3CA wild-type treatment landscape.

Bears say

Celcuity is a clinical-stage biotechnology company with a promising candidate, gedatolisib, currently in Phase 3 trials for breast cancer and prostate cancer. However, the company faces significant risks, including potential challenges with clinical and regulatory processes, manufacturing, and competition, which could impact the success and profitability of their treatments. Additionally, the company has a negative net worth and currently relies on external funding, which could lead to dilution for existing shareholders.

Celcuity (CELC) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celcuity (CELC) Forecast

Analysts have given Celcuity (CELC) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Celcuity (CELC) has a Strong Buy consensus rating as of Aug 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $151.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $151.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celcuity (CELC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.